Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: Comparison with histological fibrosis

Liver International

Volumn 35, Issue 3, 2015, Pages 1054-1062

  Shin, Seung Hwan ^a   Kim, Seung Up ^a,b   Park, Jun Yong ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b,c   Han, Kwang Hyub ^a,b,c   Kim, Beom Kyung ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

^c Brain Korea 21 Project for Medical Science   (South Korea)

Author keywords

Chronic hepatitis B; Fibroscan; Hepatitis B virus; Hepatocellular carcinoma; Liver stiffness; Platelet count; Prediction; Prognosis; Spleen size

Indexed keywords

ADULT; ARTICLE; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; ELASTOGRAPHY; FEMALE; HEPATITIS B; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MODEL; PORTAL HYPERTENSION; PREDICTION; PROGNOSIS; RIGIDITY; SCORING SYSTEM; SPLEEN DIAMETER TO PLATELET RATIO SCORE; SPLEEN SIZE; THROMBOCYTE COUNT; COMPLICATION; FOLLOW UP; HEPATITIS B, CHRONIC; LIVER; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; SPLEEN;

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SPLEEN;

EID: 84922749364     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12621     Document Type: Article

References (47)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
2. Han KH, Yoon KT. New diagnostic method for liver fibrosis and cirrhosis. Intervirology 2008; 51(Suppl. 1): 11-6.
3. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
5. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64.
6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
7. Wu YM, Xu N, Hu JY, et al. A simple noninvasive index to predict significant liver fibrosis in patients with advanced schistosomiasis japonica. Parasitol Int 2013; 62: 283-8.
8. Kim BK, Kim SA, Park YN, et al. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int 2007; 27: 969-76.
9. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
10. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91.
11. Chon YE, Jung ES, Park JY, et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol 2012; 46: 518-25.
12. Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol 2009; 50: 59-68.
13. Kazemi F, Kettaneh A, N'Kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45: 230-5.
14. Kim SU, Kim do Y, Park JY, et al. How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol 2010; 44: 66-71.
15. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8.
16. Kim BK, Han KH, Park JY, et al. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol 2010; 105: 1382-90.
17. Kim BK, Kim do Y, Han KH, et al. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol 2011; 106: 1654-62, 730.
18. Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144: 102-11.e1.
19. Colecchia A, Di Biase AR, Scaioli E, et al. Non-invasive methods can predict oesophageal varices in patients with biliary atresia after a Kasai procedure. Dig Liver Dis 2011; 43: 659-63.
20. Sharma P, Kirnake V, Tyagi P, et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices. Am J Gastroenterol 2013; 108: 1101-7.
21. Kim BK, Park YN, Kim do Y, et al. Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. Digestion 2012; 85: 219-27.
22. Dittrich M, Milde S, Dinkel E, Baumann W, Weitzel D. Sonographic biometry of liver and spleen size in childhood. Pediatr Radiol 1983; 13: 206-11.
23. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
24. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
25. Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012; 18: 109-62.
26. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
27. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
28. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
29. Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol 2009; 15: 391-423.
30. Han KH, Seong J, Kim JK, et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
31. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
32. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-41.
33. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
34. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-56.
35. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.
36. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
37. Ahn YO. Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. Gut 1996; 38(Suppl. 2): S63-6.
38. Lee KJ, Han KH, Chun JY, et al. Natural history of chronic hepatitis type B throughout long-term follow-up. Korean J Gastroenterol 1997; 29: 343-51.
39. Kim CY, Kim JW, Lee HS, Yoon YB, Song IS. Natural history and survival rate of chronic liver diseases in Korea - 20 years prospective analysis. Korean J Med 1994; 46: 168-80.
40. Triolo M, Corte CD, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int 2014; 34(Suppl. 1): 139-45.
41. Robic MA, Procopet B, Metivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011; 55: 1017-24.
42. Giannini E, Botta F, Borro P, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52: 1200-5.
43. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23: 1055-65.
44. Thabut D, Ratziu V, Trabut JB, Poynard T. Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. Gut 2004; 53: 913-4; author reply 4-5.
45. Kim BK, Han KH, Park JY, et al. Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. Liver Int 2010; 30: 860-6.
46. Kim BK, Han KH, Park JY, et al. A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. Liver Int 2010; 30: 1073-81.
47. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10: 211-31.